Ad Scientiam Press Releases - EIN Presswire - Press Release Distribution Service

Published on June 29, 2026 - 12:00 GMT

Ad Scientiam Unveils Positive Interim 1-Year Longitudinal Results for MSCopilot® at EAN 2026

PARIS, FRANCE, June 29, 2026 /⁨EINPresswire.com⁩/ -- Ad Scientiam, a pioneer in the development of clinically validated digital biomarkers, today announced the presentation of highly encouraging interim results from the ongoing MS-DETECT and MS-FLOWER …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on April 15, 2026 - 07:00 GMT

Ad Scientiam launches U.S. subsidiary and expands deployment of MSCopilot® following FDA registration

Ad Scientiam announces the creation of its U.S. subsidiary, Ad Scientiam Inc., to support the deployment of MSCopilot® in the United States. PARIS, FRANCE, April 15, 2026 /⁨EINPresswire.com⁩/ -- Ad Scientiam, a global leader in digital biomarkers, today …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 13, 2025 - 07:30 GMT

Ad Scientiam Collaborates with Merck KGaA to Launch Innovative Digital Clinical Study for Generalized Myasthenia Gravis

The study will explore how wearables, smartphone-based functional tests, and ePROs could detect changes in disease trajectory in real-world conditions PARIS, FRANCE, November 13, 2025 /⁨EINPresswire.com⁩/ -- Ad Scientiam today announced a collaboration …

Distribution channels: Business & Economy, Healthcare & Pharmaceuticals Industry ...

Published on November 5, 2025 - 13:00 GMT

TECHLIFE CAPITAL invests in AD SCIENTIAM, a pioneer in digital biomarkers for clinical & real-world patient monitoring

Ad Scientiam welcomes TechLife Capital as lead investor to boost its AI-powered digital biomarkers worldwide, leveraging patient data for real-time monitoring PARIS, FRANCE, November 5, 2025 /⁨EINPresswire.com⁩/ -- Ad Scientiam, a company specializing in …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...

Published on June 19, 2025 - 14:07 GMT

Ad Scientiam Announces Completion of Enrollment in the pivotal MS-DETECT Study

A significant milestone achieved with the completion of enrollment in MS-DETECT, one of the most ambitious digital biomarker trials conducted in MS PARIS, FRANCE, June 19, 2025 /⁨EINPresswire.com⁩/ -- Ad Scientiam, a MedTech company leader in developing …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...

Published on June 3, 2025 - 07:35 GMT

MSCopilot® receives CE marking under the European Union Medical Device Regulation (EU MDR) 2017/745

A major milestone for the digital monitoring of people living with multiple sclerosis PARIS, FRANCE, FRANCE, June 3, 2025 /⁨EINPresswire.com⁩/ -- On the occasion of World Multiple Sclerosis Day, Ad Scientiam announced that MSCopilot®, its class IIa …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Published on April 8, 2025 - 16:01 GMT

Ad Scientiam Present Promising Interim Findings on Digital Biomarkers in Myasthenia Gravis at AAN 2025

Interim results from the ME&MGopen study demonstrate strong adherence, high usability, and meaningful clinical associations in myasthenia gravis PARIS, FRANCE, April 8, 2025 /⁨EINPresswire.com⁩/ -- Ad Scientiam to Present Promising Interim Findings on …

Distribution channels: Healthcare & Pharmaceuticals Industry, Technology ...

Published on February 26, 2025 - 17:46 GMT

Ad Scientiam Launches a Pilot Project in the U.S. to Assess MSCopilot®’s Integration into Routine Care for MS Patients

Ad Scientiam launches the MS-FLOWER project in the US to integrate MSCopilot® in routine care for multiple sclerosis, enhancing monitoring and decision-making PARIS, FRANCE, February 26, 2025 /⁨EINPresswire.com⁩/ -- Ad Scientiam, a pioneering MedTech …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on September 17, 2024 - 16:43 GMT

Ad Scientiam to Provide Digital Biomarker Expertise to Abata Therapeutics in First Treg Cell Trial for Progressive MS

Ad Scientiam to provide digital biomarker expertise to Abata Therapeutics in a first-in-human Phase I clinical study of ABA-101 in patients with progressive MS PARIS, FRANCE, September 17, 2024 /⁨EINPresswire.com⁩/ -- Ad Scientiam, a global leader in …

Distribution channels: Healthcare & Pharmaceuticals Industry ...